Oral Venglustat in Parkinson’s Disease Patients With a GBA Mutation: Study Design of Part 2 of the MOVES-PD Trial and Patient Characteristics
Objective: Describe the study design of Part 2 of the MOVES-PD trial (NCT02906020), and report patient characteristics. Background: Mutations in the glucocerebrosidase (GBA) gene are…Correlation and comparison of the lipid profile and the body fat mass in people with Parkinson’s disease submitted to three physical therapies
Objective: To correlate and to compare changes on the lipid profile (LP) and on the body fat mass in people with Parkinson's disease (PD) submitted…Post mortem fatty acid abnormalities in the cerebellar cortex of patients with essential tremor
Objective: The objective of the study was to compare fatty acids (FA) profiles within different fractions of phospholipids retrieved from the cerebellum of patients who…Synaptic dysfuncion in a Drosophila model of PARK14
Objective: To investigate the association between lipid metabolism and synaptic function in Parkinson's disease (PD) due to PLA2G6 mutations. Background: The nervous system is enriched…Parkinson’s disease-associated mutations of PLA2G6 alters the membrane dynamics and α-synuclein stability
Objective: To investigate the mechanism of α-synuclein (α-Syn) aggregation. Background: PLA2G6 has been isolated as the gene responsible for an autosomal recessive form of Parkinson’s…The role of lipid metabolism in mouse models of Parkinson’s disease
Objective: To investigate the role of lipid metabolism and the effect of blocking carnitine palmitoyl-transferase 1 (CPT1) in toxic and genetically mouse models of Parkinson’s…Abnormal Gait in Cerebrotendenious Xanthomatosis a case report
Objective: To identify patients with Cererotendenious xanthomatosis. To present the neurological spectrum of the disease. Background: Cerebrotendenious xanthomatosis is a rare lipid storage disease due…Cerebrotendinous Xanthomatosis presenting Parkinsonism with bilateral iron accumulation in the basal ganglia
Objective: Cerebrontendinous xanthomatosis(CTX) is a treatable, autosomal recessive, lipid storage disorder disease. Herein, we present a case of CTX. It aims to refresh and improve…Increased level of a lysosomal phospholipid, BMP, in urine of LRRK2 G2019S mutation carriers with or without Parkinson’s disease: implications for therapeutic development
Objective: To study alterations in urinary phospholipids as biomarkers of LRRK2 mutations and Parkinson’s disease (PD) status. Background: LRRK2 mutations are a common cause of…Profiling of lipoproteins and associated lipids in serum samples from Idiopathic REM Sleep Behavior Disorder patients to identify biomarkers for Parkinson’s disease
Objective: To perform a lipidomic profile in serum samples from IRBD patients collected before and after their conversion to PD and DLB, in order to…